3-(3,5-difluoro-2-methoxyphenyl)-5-(1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-D4

3-(3,5-difluoro-2-methoxyphenyl)-5-(1-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine-D4 is a labeled version of a small molecule that is being studied for its potential use as a therapeutic agent. The compound is a pyrrolopyridine-based inhibitor of a type of enzyme called cyclin-dependent kinase (CDK) which plays a role in cell division and cancer progression. The labeled version of the compound, with four deuterium atoms substituted for hydrogen, is useful in certain types of experiments that require the use of labeled compounds to track their fate in biological systems. The chemical structure of the compound shows that it contains several functional groups, including a methoxy group, a piperidine ring, a pyrazole ring, and a pyrrolopyridine ring. These groups are important for the compound's ability to interact with the CDK enzyme and inhibit its activity. Studies have shown that the compound is effective in vitro and in vivo at inhibiting the growth of cancer cells, particularly those associated with breast cancer and lung cancer. Further research is needed to determine the compound's safety and efficacy in humans, but its potential as a therapeutic agent makes it an important target for drug development.